Outlook Therapeutics Q1 FY2026 net loss $23.1M; unit sales of LYTENAVA double in Europe

Outlook Therapeutics, Inc.

2026-Q1 EPS reported -$0.38

Net loss of $23.1M ($0.38/share) vs net income of $17.4M ($0.72/share) in prior-year quarter.
Adjusted net loss $13.5M ($0.22/share) vs adjusted net loss $21.6M ($0.89/share) a year ago.
Revenue negatively impacted by returns reserve for short-dated product from UK distributor; unit sales more than doubled QoQ.
Cash and equivalents $8.7M as of Dec 31, 2025 (excluding $2.4M ATM proceeds post-quarter).
Submitted Type A meeting request to FDA to discuss ONS-5010 CRL for wet AMD; additional EU launches planned.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001104659-26-015887
form_type: 8-K
ticker: OTLK
cik: 0001649989
company_name: Outlook Therapeutics, Inc.
filed_at: 2026-02-17T23:59:59+00:00
discovered_at: 2026-05-14T18:02:35.757352+00:00
generated_at: 2026-05-16T02:26:48.891796+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: negative
materiality_score: 0.7
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001104659-26-015887
json_url: https://secwatch.observer/filing/0001104659-26-015887.json
markdown_url: https://secwatch.observer/filing/0001104659-26-015887.md
text_url: https://secwatch.observer/filing/0001104659-26-015887.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1649989/000110465926015887/0001104659-26-015887-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1649989/000110465926015887/tm266557d1_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001104659-26-015887

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.